Grundläggande statistik
| CIK | 320174 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Perseon Corporation Warrants
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| April 27, 2017 |
15-12G 1 bsdmed15042717.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001- 32526 BSD Medical Corporation (Exact name of |
|
| January 12, 2017 |
As filed with the Securities and Exchange Commission on January 12, 2017 Registration No. |
|
| January 12, 2017 |
As filed with the Securities and Exchange Commission on January 12, 2017 Registration No. |
|
| January 12, 2017 |
As filed with the Securities and Exchange Commission on January 12, 2017 Registration No. |
|
| January 12, 2017 |
As filed with the Securities and Exchange Commission on January 12, 2017 Registration No. |
|
| January 12, 2017 |
S-8 POS 1 bsdmposs8-4011017.htm As filed with the Securities and Exchange Commission on January 12, 2017 Registration No. 333-50588 Registration No. 333-142973 Registration No. 333-157025 Registration No. 333-165885 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-50588 Post-Effective Amendment No. 1 t |
|
| January 12, 2017 |
As filed with the Securities and Exchange Commission on January 12, 2017 Registration No. |
|
| January 12, 2017 |
S-8 POS 1 bsdmposs8-3011017.htm As filed with the Securities and Exchange Commission on January 12, 2017 Registration No. 333-50588 Registration No. 333-142973 Registration No. 333-157025 Registration No. 333-165885 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-50588 Post-Effective Amendment No. 1 t |
|
| January 3, 2017 |
EX-99.3 5 ex993.htm NOVEMBER 2016 MONTHLY OPERATING REPORT EXHIBIT 99.3 |
|
| January 3, 2017 |
EXHIBIT 2.1 |
|
| January 3, 2017 |
8-K 1 bsd8k123016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2016 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of in |
|
| January 3, 2017 |
EX-99.1 3 ex991.htm FINDINGS AND CONCLUSIONS OF THE BANKRUPTCY COURT EXHIBIT 99.1 Prepared and Submitted By: Steven T. Waterman (4164) Michael F. Thomson (9707) Jeffrey M. Armington (14050) DORSEY & WHITNEY LLP136 South Main Street, Suite 1000 Salt Lake City, UT 84101-1685Telephone: (801) 933-7360Facsimile: (801) 933-7373Email: [email protected] thomson.michael @dorsey.com armington.jeff@ |
|
| January 3, 2017 |
EX-99.2 4 ex992.htm ORDER CONFIRMING COMPANY'S PLAN EXHIBIT 99.2 |
|
| November 30, 2016 |
EXHIBIT 99.1 |
|
| November 30, 2016 |
EXHIBIT 99.2 |
|
| November 30, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 bsd8k113016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2016 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of inc |
|
| November 7, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 1-32526 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2016 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐ Transition Report on Form 11-K For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| October 13, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2016 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commiss |
|
| October 13, 2016 |
EX-99.1 2 ex991.htm OPERATING REPORT EXHIBIT 99.1 |
|
| September 13, 2016 |
8-K 1 bsd8k09082016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2016 BSD Medical Corporation (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of |
|
| August 25, 2016 |
8-K 1 bsd8k08152016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2016 BSD Medical Corporation (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of in |
|
| August 25, 2016 |
8-K 1 bsd8k08152016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2016 BSD Medical Corporation (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of in |
|
| August 25, 2016 |
EX-99.1 4 wz991.htm OPERATING REPORTS EXHIBIT 99.1 |
|
| August 25, 2016 |
EX-3.1 2 ex31.htm FOURTH CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PERSEON CORPORATION EXHIBIT 3.1 FOURTH CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PERSEON CORPORATION PERSEON Corporation (the “Corporation”), a corporation duly organized and existing under the Delaware General Corporation Law (the “DGCL”), does h |
|
| August 25, 2016 |
EX-99.1 4 wz991.htm OPERATING REPORTS EXHIBIT 99.1 |
|
| August 25, 2016 |
AMENDED AND RESTATED BY-LAWS OF BSD MEDICAL CORPORATION ARTICLE I. EX-3.2 3 ex32.htm AMENDED AND RESTATED BYLAWS OF BSD MEDICAL CORPORATION EXHIBIT 3.2 AMENDED AND RESTATED BY-LAWS OF BSD MEDICAL CORPORATION ARTICLE I. OFFICES Section 1. Additional Offices. The Corporation may have, in addition to its registered office, offices and places of business at such places, both within and without the State of Delaware as the Board of Directors may from time to time dete |
|
| August 25, 2016 |
EX-3.1 2 ex31.htm FOURTH CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PERSEON CORPORATION EXHIBIT 3.1 FOURTH CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PERSEON CORPORATION PERSEON Corporation (the “Corporation”), a corporation duly organized and existing under the Delaware General Corporation Law (the “DGCL”), does h |
|
| August 25, 2016 |
AMENDED AND RESTATED BY-LAWS OF BSD MEDICAL CORPORATION ARTICLE I. EX-3.2 3 ex32.htm AMENDED AND RESTATED BYLAWS OF BSD MEDICAL CORPORATION EXHIBIT 3.2 AMENDED AND RESTATED BY-LAWS OF BSD MEDICAL CORPORATION ARTICLE I. OFFICES Section 1. Additional Offices. The Corporation may have, in addition to its registered office, offices and places of business at such places, both within and without the State of Delaware as the Board of Directors may from time to time dete |
|
| August 9, 2016 |
NT 10-Q 1 perseon12b25-06302016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 1-32526 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2016 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on For |
|
| July 22, 2016 |
MONTHLY OPERATING REPORT CHAPTER 11 ex991.htm Exhibit 99.1 DEBTOR: Perseon Corporation MONTHLY OPERATING REPORT CHAPTER 11 CASE NUMBER: 16-24435 RKM Form 2-A COVER SHEET For Period Ending: 5/23/2016 to 5/31/2016 Accounting Method: ☒ Accrual Basis ☐ Cash Basis THIS REPORT IS DUE 14 DAYS AFTER THE END OF THE MONTH Debtor must attach each of the following reports/documents unless the U. S. Trustee has waived the requirement in writing. |
|
| July 22, 2016 |
8-K 1 perseon8k07182016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2016 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of inco |
|
| June 15, 2016 |
NT 10-Q 1 perseon-nt12b25061516.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 1-32526 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2016 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Fo |
|
| June 15, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2016 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commission File |
|
| June 15, 2016 |
Perseon Medical Balance Sheet (Unaudited) April 2016 EX-99.1 2 ex991.htm UNAUDITED FINANCIALS EXHIBIT 99.1 Perseon Medical Balance Sheet (Unaudited) April 2016 ASSETS Current Assets Wells Fargo - Restriced Cash 25,000.00 Cash in bank-Payroll 4,665.12 Cash in bank-Wells Fargo 121,220.23 Money Market- Wells Fargo 188,350.23 Accounts Receivable-Trade 551,210.44 Allowance for Doubtful Accts. (66,480.00 ) Raw Materials 341,160.73 Raw materials at CEA 4,5 |
|
| May 23, 2016 |
424B3 1 perseon8k424b3-05232016.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-203592 Prospectus Supplement No. 12 (to Prospectus dated July 29, 2015) 13,225,000 shares of Common Stock issuable upon the exercise of the 13,225,000 outstanding Warrants issued in our public offering This prospectus supplement supplements the prospectus dated July 29, 2015, as supplemented by prospectus sup |
|
| May 23, 2016 |
8-K 1 perseon8k05232016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2016 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incor |
|
| May 23, 2016 |
Unassociated Document EXHIBIT 2.1 ASSET PURCHASE AGREEMENT between PERSEON CORPORATION and MEDLINK TECHNOLOGIES, LLC dated as of May 17, 2016 TABLE OF CONTENTS CONTENTS Article I. Definitions 1 Article II. Purchase and Sale 5 Section 2.01 Purchase and Sale of Assets 5 Section 2.02 Excluded Assets 7 Section 2.03 Assumed Liabilities 7 Section 2.04 Excluded Liabilities 8 Section 2.05 Purchase Price 8 |
|
| May 23, 2016 |
EX-10.1 3 ex101.htm EXHIBIT 10.1 LICENSE AGREEMENT This license agreement (the "Agreement"), dated las of May 16, 2016, is entered into between Perseon Corporation, a Delaware corporation having a principal place of business at 391 Chipeta Way, Suite F, Salt Lake City, Utah 84108 ("Licensor"), and Medlink Technologies, LLC, a North Carolina limited liability company, having a principal place of bu |
|
| March 31, 2016 |
NT 10-K 1 perseon12b25123115.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 1-32526 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2015 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Fo |
|
| March 31, 2016 |
424B3 1 perseon424b3-no11033016.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-203592 Prospectus Supplement No. 11 (to Prospectus dated July 29, 2015) 13,225,000 shares of Common Stock issuable upon the exercise of the 13,225,000 outstanding Warrants issued in our public offering This prospectus supplement supplements the prospectus dated July 29, 2015, as supplemented by prospectus sup |
|
| March 31, 2016 |
Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2016 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commission File |
|
| February 26, 2016 |
424B3 1 perseon424b3-no10022516.htm Registration No. 333-203592 Prospectus Supplement No. 10 (to Prospectus dated July 29, 2015) 13,225,000 shares of Common Stock issuable upon the exercise of the 13,225,000 outstanding Warrants issued in our public offering This prospectus supplement supplements the prospectus dated July 29, 2015, as supplemented by prospectus supplement No. 1 dated August 19, 20 |
|
| February 26, 2016 |
Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets 8-K 1 perseon8k022516.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2016 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of in |
|
| February 12, 2016 |
PRSN / Perseon Corporation / CAPITAL VENTURES INTERNATIONAL - SC 13G/A Passive Investment SC 13G/A 1 a16-372627sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Perseon Corporation (Name of Issuer) Common Stock, $.001 par value per share (Title of Class of Securities) 71527 |
|
| January 28, 2016 |
Unassociated Document Filed Pursuant to Rule 424(b)(3) Registration No. 333-203592 Prospectus Supplement No. 9 (to Prospectus dated July 29, 2015) 13,225,000 shares of Common Stock issuable upon the exercise of the 13,225,000 outstanding Warrants issued in our public offering This prospectus supplement supplements the prospectus dated July 29, 2015, as supplemented by prospectus supplement No. 1 d |
|
| January 28, 2016 |
SUBLEASE TERMINATION AGREEMENT ex101.htm EXHIBIT 10.1 SUBLEASE TERMINATION AGREEMENT This Sublease Termination Agreement (this ?Agreement?) is dated as of January 21, 2016 and is by and between EnergySolutions, LLC (?Sublessor?) and Perseon Corporation (?Sublessee?). WHEREAS, Sublessor and Sublessee are parties to that certain Sublease Agreement dated as of May 14, 2015, as amended by that Amendment to Sublease Agreement dated |
|
| January 28, 2016 |
perseon8k01222016.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2016 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorpo |
|
| January 11, 2016 |
perseon8k010816.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2015 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorpor |
|
| January 11, 2016 |
424B3 1 perseon424b3-no8010816.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-203592 Prospectus Supplement No. 8 (to Prospectus dated July 29, 2015) 13,225,000 shares of Common Stock issuable upon the exercise of the 13,225,000 outstanding Warrants issued in our public offering This prospectus supplement supplements the prospectus dated July 29, 2015, as supplemented by prospectus suppl |
|
| January 4, 2016 |
perseon424b3-no7123015.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-203592 Prospectus Supplement No. 7 (to Prospectus dated July 29, 2015) 13,225,000 shares of Common Stock issuable upon the exercise of the 13,225,000 outstanding Warrants issued in our public offering This prospectus supplement supplements the prospectus dated July 29, 2015, as supplemented by prospectus supplement No |
|
| January 4, 2016 |
perseon8k123015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2015 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorpor |
|
| December 22, 2015 |
Galil Medical Tender Offer to Acquire Perseon Corporation Expires EX-99.(A)(1)(XI) 2 a15-250806ex99da1xi.htm EX-99.(A)(1)(XI) Exhibit (a)(1)(xi) Galil Medical Tender Offer to Acquire Perseon Corporation Expires ARDEN HILLS, Minn., and SALT LAKE CITY, Dec. 22, 2015 — Galil Medical Ltd. (“Galil”), a global leader in delivering innovative cryotherapy ablation solutions, today announced the expiration of the previously announced tender offer by Galil’s indirect whol |
|
| December 22, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) Perseon Corporation (Name of Subject Company (Issuer)) GALIL MERGER SUB, INC. (Offeror) A wholly-owned subsidiary of GALIL MEDICAL INC. (Offeror) A wholly-owned subsidiary of GALIL MEDICAL LTD. (Offero |
|
| December 22, 2015 |
EX-99.(D)(4) 3 a15-250806ex99dd4.htm EX-99.(D)(4) Exhibit (d)(4) December 22, 2015 Perseon Corporation 460 West 50 North Salt Lake City, UT 84101 Attention: Scott Mayfield, Director of Finance Re: Termination of Agreement and Plan of Merger among Galil Medical, Inc., Galil Merger Sub, Inc. and Perseon Corporation dated October 26, 2015 Dear Mr. Mayfield, Please be advised that Galil Medical, Inc. |
|
| December 22, 2015 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 perseon8-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2015 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction o |
|
| December 22, 2015 |
424B3 1 perseon424b3.htm PROSPECTUS SUPPLEMENT NO. 6 Filed Pursuant to Rule 424(b)(3) Registration No. 333-203592 Prospectus Supplement No. 6 (to Prospectus dated July 29, 2015) 13,225,000 shares of Common Stock issuable upon the exercise of the 13,225,000 outstanding Warrants issued in our public offering This prospectus supplement supplements the prospectus dated July 29, 2015, as supplemented b |
|
| December 22, 2015 |
Perseon SCHEDULE 14D9-AMENDMENT NO. 3 SC 14D9/A 1 perseonsc14d9-a.htm SCHEDULE 14D9-AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Amendment No. 3 PERSEON CORPORATION (Name of Subject Company) PERSEON CORPORATION (Name of Persons Filing Statement) Common Stock, par v |
|
| December 2, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Perseon Corporation (Name of Subject Company (Issuer)) GALIL MERGER SUB, INC. (Offeror) A wholly-owned subsidiary of GALIL MEDICAL INC. (Offeror) A wholly-owned subsidiary of GALIL MEDICAL LTD. (Offero |
|
| December 2, 2015 |
Perseon SCHEDULE 14D9-AMENDMENT NO. 2 SC 14D9/A 1 perseonsc14d9-a.htm SCHEDULE 14D9-AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Amendment No. 2 PERSEON CORPORATION (Name of Subject Company) PERSEON CORPORATION (Name of Persons Filing Statement) Common Stock, par v |
|
| December 2, 2015 |
Galil Medical/Perseon Corporation Tender Offer Update Conference Call EX-99.2 3 exhibit99-2.htm TRANSCRIPT OF CONFERENCE CALL HELD DECEMBER 2, 2015 Exhibit 99.2 Galil Medical/Perseon Corporation Tender Offer Update Conference Call Operator Good morning and thank you for joining us today to discuss an update to Galil Medical's tender offer for the shares of common stock and publicly traded warrants of Perseon Corporation, followed by a merger of Galil and Perseon und |
|
| December 2, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2015 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 2, 2015 |
Galil Medical Extends Tender Offer Period to Acquire Perseon Corporation Exhibit 99.1 Galil Medical Extends Tender Offer Period to Acquire Perseon Corporation Arden Hills, MN, and Salt Lake City, UT? December 2, 2015 ? Galil Medical Ltd. ('Galil"), a global leader in delivering innovative cryotherapy ablation solutions, today announced Galil's indirect wholly owned subsidiary Galil Merger Sub, Inc. has extended its previously announced tender offer to purchase (i) all |
|
| December 2, 2015 |
424B3 1 perseon424b3.htm PROSPECTUS SUPPLEMENT NO. 5 Filed Pursuant to Rule 424(b)(3) Registration No. 333-203592 Prospectus Supplement No. 5 (to Prospectus dated July 29, 2015) 13,225,000 shares of Common Stock issuable upon the exercise of the 13,225,000 outstanding Warrants issued in our public offering This prospectus supplement supplements the prospectus dated July 29, 2015, as supplemented b |
|
| November 30, 2015 |
EX-99.1 2 exhibit99-1.htm PRESS RELEASE DATED NOVEMBER 30, 2015 Exhibit 99.1 Galil Medical and Perseon Corporation Announce Tender Offer/Merger Information Call Conference Call and Webcast Scheduled for Wednesday, December 2 at 11:00 a.m. Eastern Time/9:00 a.m. Mountain Time Arden Hills, MN, and Salt Lake City, UT– November 30, 2015 – Galil Medical ("Galil"), a global leader in delivering innovati |
|
| November 30, 2015 |
Perseon SCHEDULE 14D9-AMENDMENT NO. 1 SC 14D9/A 1 perseonsc14d9-a.htm SCHEDULE 14D9-AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Amendment No. 1 PERSEON CORPORATION (Name of Subject Company) PERSEON CORPORATION (Name of Persons Filing Statement) Common Stock, par v |
|
| November 30, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 perseon8-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2015 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction o |
|
| November 30, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Perseon Corporation (Name of Subject Company (Issuer)) GALIL MERGER SUB, INC. (Offeror) A wholly-owned subsidiary of GALIL MEDICAL INC. (Offeror) A wholly-owned subsidiary of GALIL MEDICAL LTD. (Offero |
|
| November 5, 2015 |
Exhibit (a)(1)(v) OFFER TO PURCHASE FOR CASH ALL OUTSTANDING SHARES OF COMMON STOCK OF PERSEON CORPORATION AT $1. |
|
| November 5, 2015 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 5, 2015 |
Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares or Public Warrants (each as defined below). |
|
| November 5, 2015 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY FOR TENDER OF SHARES OF COMMON STOCK OF PERSEON CORPORATION OR PUBLICLY-TRADED WARRANTS TO PURCHASE SHARES OF COMMON STOCK OF PERSEON CORPORATION (Not to be used for signature guarantees) THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 PM, NEW YORK CITY TIME, ON DECEMBER 7, 2015, UNLESS THE OFFER IS EXTENDED. |
|
| November 5, 2015 |
MUTUAL CONFIDENTIALITY AGREEMENT EX-99.(E)(2) 2 a2226442zex-99e2.htm EX-99.(E)(2) Exhibit (e)(2) MUTUAL CONFIDENTIALITY AGREEMENT This Mutual Confidentiality Agreement (“Agreement”) is entered into effective as of March 16, 2015 (the “Effective Date”) by and between Galil Medical, Inc., and Perseon Corporation, a Delaware corporation. The parties wish to protect and preserve the confidential and/or proprietary nature of informati |
|
| November 5, 2015 |
Use these links to rapidly review the document Table of Contents REPORT OF INDEPENDENT AUDITORS To the Board of Directors and Shareholders of GALIL MEDICAL LTD. |
|
| November 5, 2015 |
Exhibit (a)(1)(iv) OFFER TO PURCHASE FOR CASH ALL OUTSTANDING SHARES OF COMMON STOCK OF PERSEON CORPORATION AT $1. |
|
| November 5, 2015 |
MUTUAL CONFIDENTIALITY AGREEMENT Exhibit (d)(2) MUTUAL CONFIDENTIALITY AGREEMENT This Mutual Confidentiality Agreement (?Agreement?) is entered into effective as of March 16, 2015 (the ?Effective Date?) by and between Galil Medical, Inc. |
|
| November 5, 2015 |
Annex A Perseon Capital Structure See Attachment Exhibit (d)(3) September 26, 2015 Perseon Corporation 2188 West 2200 South Salt Lake City, UT 84119 Attn: Board of Directors Gentlemen: It has been a pleasure to interact with the management team and advisors of Perseon Corporation (?Perseon? or ?you?) over the last few months. |
|
| November 5, 2015 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 5, 2015 |
Annex A Perseon Capital Structure See Attachment Exhibit (e)(3) September 26, 2015 Perseon Corporation 2188 West 2200 South Salt Lake City, UT 84119 Attn: Board of Directors Gentlemen: It has been a pleasure to interact with the management team and advisors of Perseon Corporation (?Perseon? or ?you?) over the last few months. |
|
| November 5, 2015 |
EX-99.(A)(1)(II) 3 a2226441zex-99a1ii.htm EX-99.(A)(1)(II) QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(ii) Letter of Transmittal To Tender Shares of Common Stock (CUSIP 715270 203) and Publicly-Traded Warrants to Purchase Shares of Common Stock (CUSIP 715270 112) of PERSEON CORPORATION At $1.00 Net Per Share or $0.02 Net Per Public Warrant in Cash Pursuant to t |
|
| October 27, 2015 |
Perseon PERSEON CORPORATION 10Q 2015-09-30 (Quarterly Report) 10-Q 1 perseon.htm PERSEON CORPORATION 10Q 2015-09-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2015 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition per |
|
| October 27, 2015 |
SC TO-C 1 v422888sctoc.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Perseon Corporation (Name of Subject Company) GALIL MERGER SUB, INC. (Offeror) A wholly-owned subsidiary of GALIL MEDICAL INC. (Offeror) A wholly-owned subsidiary of GALIL MEDICAL LTD. |
|
| October 27, 2015 |
Amendment to Sublease Agreement between the Company and EnergySolutions, LLC perseonexh103.htm Exhibit 10.3 Amendment to Sublease Agreement between the Company and EnergySolutions, LLC AMENDMENT TO SUBLEASE AGREEMENT This Amendment to Sublease Agreement (this ?Amendment?) is entered into on August 25, 2015 (the ?Effective Date?) by and between EnergySolutions, LLC, a Utah limited liability company (?Sublessor?), and Perseon Corporation, a Delaware corporation (?Sublessee?) |
|
| October 27, 2015 |
Exhibit 99.1 Galil Medical Enters into Agreement to Acquire Perseon Corporation to Create Leader in Ablation Treatment for Tumors ? Transaction brings scale and cost savings to create high growth, high margin market opportunity capitalizing on increased global distribution ? Hot and cold combination provides powerful tool kit for interventional radiologists ? Galil Medical to pay $1.00 per Perseon |
|
| October 27, 2015 |
exhibit99-1.htm Exhibit 99.1 Galil Medical Enters into Agreement to Acquire Perseon Corporation to Create Leader in Ablation Treatment for Tumors ? Transaction brings scale and cost savings to create high growth, high margin market opportunity capitalizing on increased global distribution ? Hot and cold combination provides powerful tool kit for interventional radiologists ? Galil Medical to pay $ |
|
| October 27, 2015 |
exhibit2-1.htm Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among GALIL MEDICAL, INC. GALIL MERGER SUB, INC. and PERSEON CORPORATION Dated as of October 26, 2015 TABLE OF CONTENTS Page ARTICLE I THE OFFER 2 Section 1.1 The Offer 2 Section 1.2 Offer Documents 3 Section 1.3 Company Actions 4 Section 1.4 Directors 5 Section 1.5 Short Form Merger 6 ARTICLE II THE MERGER 7 Section 2.1 The Merger 7 Section |
|
| October 27, 2015 |
perseonexh322.htm EXHIBIT 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Perseon Corporation (the ?Company?) on Form 10-Q for the quarterly period ended September 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), I, William S. Barth |
|
| October 27, 2015 |
SC14D9C 1 perseonsc14d-9.htm SCHEDULE 14D-9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 PERSEON CORPORATION (Name of Subject Company) PERSEON CORPORATION (Name of Persons Filing Statement) Common Stock, par value $0.001 per share Warrants to |
|
| October 27, 2015 |
perseon424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-203592 Prospectus Supplement No. 4 (to Prospectus dated July 29, 2015) 13,225,000 shares of Common Stock issuable upon the exercise of the 13,225,000 outstanding Warrants issued in our public offering This prospectus supplement supplements the prospectus dated July 29, 2015, as supplemented by prospectus supplement No. 1 dated |
|
| October 27, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2015 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 27, 2015 |
Exhibit 99.2 GALIL MEDICAL ANNOUNCES AGREEMENT TO ACQUIRE PERSEON CORPORATION 100% cash tender will commence; closing contingent on raising approximately $26M in new debt/equity Arden Hills, MN?October 27, 2015 ? Galil Medical, the global leader in interventional oncology cryoablation technology, announced today it has entered into an agreement to acquire 100% of Perseon Corporation, a publicly-tr |
|
| September 15, 2015 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2015 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commission |
|
| September 15, 2015 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-203592 Prospectus Supplement No. 3 (to Prospectus dated July 29, 2015) 13,225,000 shares of Common Stock issuable upon the exercise of the 13,225,000 outstanding Warrants issued in our public offering This prospectus supplement supplements the prospectus dated July 29, 2015, as supplemented by prospectus supplement No. 1 dated August 19, 2015, |
|
| September 1, 2015 |
424B3 1 perseon424b3-no2090115.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-203592 Prospectus Supplement No. 2 (to Prospectus dated July 29, 2015) 13,225,000 shares of Common Stock issuable upon the exercise of the 13,225,000 outstanding Warrants issued in our public offering This prospectus supplement supplements the prospectus dated July 29, 2015 (the “Prospectus”), as supplemented |
|
| September 1, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2015 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 1, 2015 |
Perseon CFO William Barth Announces Plans to Retire EX-99.1 2 ex991.htm PRESS RELEASE EXHIBIT 99.1 Perseon CFO William Barth Announces Plans to Retire Salt Lake City – September 1, 2015 – Perseon Corporation (NASDAQ: PRSN) (“Perseon” or the “Company”), a leading provider of medical systems that utilize energy to treat cancer, today announced that Chief Financial Officer William Barth, 65, has advised the Company of his plans to retire. Perseon has |
|
| August 19, 2015 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2015 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 19, 2015 |
424B3 1 perseon424b308192015.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-203592 Prospectus Supplement No. 1 (to Prospectus dated July 29, 2015) 13,225,000 shares of Common Stock issuable upon the exercise of the 13,225,000 outstanding Warrants issued in our public offering This prospectus supplement supplements the prospectus dated July 29, 2015 (the “Prospectus”), which relates to t |
|
| August 7, 2015 |
PRSN / Perseon Corporation / CAPITAL VENTURES INTERNATIONAL - SC 13G Passive Investment CUSIP No. 715270203 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Perseon Corporation (Name of Issuer) Common Stock, $.001 par value per share (Title of Class of Securities) 715270203 (CUSIP Number |
|
| August 4, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2015 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commission File |
|
| July 30, 2015 |
5,750,000 shares of Common Stock and Warrants to purchase 11,500,000 shares of Common Stock 424B4 1 perseon.htm PERSEON CORPORATION 424B4 2015-07-29 5,750,000 shares of Common Stock and Warrants to purchase 11,500,000 shares of Common Stock We are offering by this prospectus 5,750,000 shares of our common stock, $0.001 par value per share, together with warrants to purchase 11,500,000 shares of our common stock. One share of common stock is being sold together with two warrants. Each war |
|
| July 28, 2015 |
PERSEON CORPORATION OTC STOCK TRANSFER, INC. WARRANT AGREEMENT Dated as of [________], 2015 EX-4.1 2 ex4-1.htm FORM OF WARRANT AGREEMENT WITH FORM OF WARRANT Exhibit 4.1 and Exhibit 4.10 PERSEON CORPORATION And OTC STOCK TRANSFER, INC. WARRANT AGREEMENT Dated as of [], 2015 THIS WARRANT AGREEMENT (this “Agreement”), dated as of [], 2015 is by and between Perseon Corporation, a Delaware corporation (the “Company”), and OTC Stock Transfer, Inc., a Utah corporation, as warrant agent (the “W |
|
| July 28, 2015 |
Perseon PERSEON CORPORATION S-1A4 2015-07-28 S-1/A 1 perseon.htm PERSEON CORPORATION S-1A4 2015-07-28 As filed with the Securities and Exchange Commission on July 28, 2015 Registration Statement No. 333-203592 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 4 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Perseon Corporation (Exact name of registrant as specified in its charter) Dela |
|
| July 27, 2015 |
Perseon Corporation UNDERWRITING AGREEMENT Exhibit 1.1 Perseon Corporation UNDERWRITING AGREEMENT July [·], 2015 MAXIM GROUP LLC 405 Lexington Avenue New York, NY 10174 As Representative of the Underwriters named on Schedule I hereto Ladies and Gentlemen: The undersigned, Perseon Corporation, a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the |
|
| July 27, 2015 |
As filed with the Securities and Exchange Commission on July 27, 2015 S-1/A 1 perseon.htm PERSEON CORPORATION S-1A3 2015-07-27 As filed with the Securities and Exchange Commission on July 27, 2015 Registration Statement No. 333-203592 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Perseon Corporation (Exact name of registrant as specified in its charter) Dela |
|
| July 27, 2015 |
July 27, 2015 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 27, 2015 |
PERSEON CORPORATION OTC STOCK TRANSFER, INC. WARRANT AGREEMENT Dated as of [________], 2015 EX-4.1 3 ex4-1.htm FORM OF WARRANT AGREEMENT WITH FORM OF WARRANT Exhibit 4.1 and Exhibit 4.10 PERSEON CORPORATION And OTC STOCK TRANSFER, INC. WARRANT AGREEMENT Dated as of [], 2015 THIS WARRANT AGREEMENT (this “Agreement”), dated as of [], 2015 is by and between Perseon Corporation, a Delaware corporation (the “Company”), and OTC Stock Transfer, Inc., a Utah corporation, as warrant agent (the “W |
|
| July 27, 2015 |
COMMON STOCK PURCHASE WARRANT PERSEON CORPORATION Exhibit 4.2 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED, OR BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT, OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF SUCH SECURITIES BY ANY PERSON FOR A PERIOD OF ONE HUNDRED AND EIGHTY (180) DAYS IMMEDIATELY FOLLOWING THE DATE OF EFFE |
|
| July 24, 2015 |
Perseon PERSEON CORPORATION 8-A12B 2015-12-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Perseon Corporation (Exact name of registrant as specified in its charter) Delaware 75-1590407 (State of incorporation or organization) (I.R.S. Employer Identification No.) 2188 West 2200 South S |
|
| July 17, 2015 |
COMMON STOCK PURCHASE WARRANT PERSEON CORPORATION Exhibit 4.2 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED, OR BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT, OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF SUCH SECURITIES BY ANY PERSON FOR A PERIOD OF ONE HUNDRED AND EIGHTY (180) DAYS IMMEDIATELY FOLLOWING THE DATE OF EFFE |
|
| July 17, 2015 |
Perseon Corporation UNDERWRITING AGREEMENT Exhibit 1.1 Perseon Corporation UNDERWRITING AGREEMENT July [·], 2015 MAXIM GROUP LLC 405 Lexington Avenue New York, NY 10174 As Representative of the Underwriters named on Schedule I hereto Ladies and Gentlemen: The undersigned, Perseon Corporation, a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the |
|
| July 17, 2015 |
PERSEON CORPORATION OTC STOCK TRANSFER, INC. WARRANT AGREEMENT Dated as of [________], 2015 Exhibit 4.1 and Exhibit 4.10 PERSEON CORPORATION And OTC STOCK TRANSFER, INC. WARRANT AGREEMENT Dated as of [], 2015 THIS WARRANT AGREEMENT (this “Agreement”), dated as of [], 2015 is by and between Perseon Corporation, a Delaware corporation (the “Company”), and OTC Stock Transfer, Inc., a Utah corporation, as warrant agent (the “Warrant Agent”, also collectively referred to herein as the “Transf |
|
| July 17, 2015 |
As filed with the Securities and Exchange Commission on July 16, 2015 As filed with the Securities and Exchange Commission on July 16, 2015 Registration Statement No. |
|
| July 16, 2015 |
EX-10.25 3 perseonexh1025.htm COMMERCIAL REAL ESTATE PURCHASE CONTRACT DATED MAY 15, 2015 BETWEEN THE COMPANY AND THE WORLD MISSION SOCIETY CHURCH OF GOD. Exhibit 10.25 This is a legally binding contract. It has been prepared by the Utah Association of REALTORS® for the use of its members only, in their transactions with clients and customers. Parties to this Commercial Real Estate Contract (“Cont |
|
| July 16, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 perseoncorporation8k.htm PERSEON CORPORATION 8K 2015-07-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2015 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 |
|
| July 16, 2015 |
EX-99.1 2 perseonexh991.htm PRESS RELEASE DATED JULY 16, 2015 Exhibit 99.1 Perseon Announces Fiscal Year 2015 Second Quarter Results; MicroThermX® Revenue Grows 117% Year-over-Year § Q2 2015 Revenues Driven Solely by the Company’s MicroThermX® Business § MicroThermX Revenues More than Doubled Year-over-Year § Reiterates Revenue Guidance of $3.5 Million to $5.0 Million for FY 2015 Salt Lake City – |
|
| July 16, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2015 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-32526 Perseon Corporati |
|
| July 16, 2015 |
Sublease Agreement between the Company and EnergySolutions, LLC Exhibit 10.24 Sublease Agreement between the Company and EnergySolutions, LLC SUBLEASE AGREEMENT This Sublease Agreement (the ?Sublease?) is executed this 14th day of May, 2015 (?Effective Date?), by and between EnergySolutions, LLC, a Utah limited liability company (?Sublessor?), and Perseon Corporation, a Delaware corporation (?Sublessee?) WITNESSETH: WHEREAS, Gateway Office 6, L.C., a Utah limi |
|
| July 16, 2015 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2015 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commission File |
|
| June 22, 2015 |
EX-3.1 2 perseonexh31.htm THIRD CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PERSEON CORPORATION Exhibit 3.1 THIRD CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PERSEON CORPORATION PERSEON Corporation (the “Corporation”), a corporation duly organized and existing under the Delaware General Corporation Law (the “DGCL”), |
|
| June 22, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2015 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commission File |
|
| May 29, 2015 |
Unassociated Document Exhibit 1.01 Conflict Minerals Report of Perseon Corporation in Accordance with Rule 13p-1 under the Securities Exchange Act of 1934 This report has been prepared by management of Perseon (formerly BSD Medical) Corporation (herein referred to as ?Perseon,? the ?Company,? ?we,? ?us,? or ?our?). The Company does not have any subsidiaries or variable interest entities that are r |
|
| May 29, 2015 |
Perseon PERSEON CORPORATION FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Perseon Corporation (Exact Name of Registrant as Specified in Charter) Delaware 001-32526 75-1590407 (State or Other Jurisdiction of Incorporation) (Commission File No.) (I.R.S. Employer Identification Number) 2188 West 2200 South, Salt Lake City, Utah 84119 (Address of Principal Executive |
|
| May 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 persepm.htm PERSEON CORPORATION 10Q 2015-03-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2015 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period |
|
| May 14, 2015 |
Employment Agreement between the Company and Brian Meltzer. Exhibit 10.23 Employment Agreement between the Company and Brian Meltzer. EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into effective as of April 1, 2015 (the ?Effective Date?), by and between Perseon Corporation, a Delaware corporation (the ?Company?) and Brian Meltzer, an individual (the ?Executive?). The Company and the Executive are r |
|
| May 14, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2015 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 14, 2015 |
Perseon Announces Financial Results for First Quarter Fiscal Year 2015 perseonexh991.htm Exhibit 99.1 Perseon Announces Financial Results for First Quarter Fiscal Year 2015 Salt Lake City ? May 14, 2015 ? Perseon Corporation (NASDAQ:PRSN) (Perseon or the Company), a leading provider of medical systems that utilize energy to treat cancer, today announced year-to-date operational highlights and financial results for the first quarter ended March 31, 20151. First Quarte |
|
| May 13, 2015 |
Submission of Matters to a Vote of Security Holders 8-K 1 perseon8k051215.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2015 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorpo |
|
| May 13, 2015 |
Perseon PERSEON CORPORATION S-1A1 2015-05-13 As filed with the Securities and Exchange Commission on May 13, 2015 Registration Statement No. |
|
| May 11, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2015 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commission File |
|
| May 6, 2015 |
8-K 1 perseon.htm PERSEON CORPORATION 8K 2015-05-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2015 PERSEON CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or othe |
|
| April 29, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2015 Perseon Corporation (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commission File |
|
| April 23, 2015 |
Perseon PERSEON CORPORATION S-1 2015-04-22 S-1 1 perseon.htm PERSEON CORPORATION S-1 2015-04-22 As filed with the Securities and Exchange Commission on April 23, 2015 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Perseon Corporation (Exact name of registrant as specified in its charter) Delaware 3845 75-1590407 (State |
|
| April 16, 2015 |
Perseon PERSEON CORPORATION DEF 14A 2015-04-15 DEF 14A 1 perseon.htm PERSEON CORPORATION DEF 14A 2015-04-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Onl |
|
| April 1, 2015 |
EX-10.2 3 perseonexh102.htm SHORT TERM LEASE FOR PERSEON CORPORATION AND PYREXAR MEDICAL INC. DATED APRIL 1, 2015 Exhibit 10.2 Short Term Lease for PERSEON CORPORATION, a Delaware corporation Landlord and PYREXAR MEDICAL INC., a Nevada corporation Tenant Table of Contents Basic Lease Information PAGE 1. Definitions 1.1 Location of Definitions; Basic Lease Information 1 2. Premises 2.1 Premises Def |
|
| April 1, 2015 |
Perseon PERSEON CORPORATION 8K 2015-04-01 (Current Report/Significant Event) perseon.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2015 Perseon Corporation (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Comm |
|
| April 1, 2015 |
perseonexh101.htm Exhibit 10.1 ASSET PURCHASE AGREEMENT by and among Perseon Corporation and Pyrexar Medical Inc. Dated as of April 1, 2015 TABLE OF CONTENTS ARTICLE 1 PURCHASE AND SALE OF ASSETS PAGE 1.1 Purchase and Sale of Assets 1 1.2 Excluded Assets 1 1.3 Assumption of Assumed Liabilities 2 1.4 Retained Liabilities 2 1.5 Payment of Purchase Price 2 1.6 Proration 3 1.7 Purchase Price Allocatio |
|
| March 31, 2015 |
Perseon PERSEON CORPORATION PRE 14A 2015-03-30 perseon.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| March 31, 2015 |
EXECUTIVE EMPLOYMENT AGREEMENT EX-10.18 2 perseonexh1018.htm EMPLOYMENT AGREEMENT WITH EFFECTIVE DATE OF FEBRUARY 16, 2015 BETWEEN THE COMPANY AND BENJAMIN BECKHAM. Exhibit 10.18 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into effective as of February 16, 2015 (the “Effective Date”), by and between Perseon Corporation, a Delaware corporation (“Perseon” or the “Compan |
|
| March 31, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [ ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended or [X] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 - For the Transition Period From September 1, 2014 to December 31, 2014 Commission File Number: |
|
| March 31, 2015 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.19 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into effective as of February 17, 2015 (the ?Effective Date?), by and between Perseon Corporation, a Delaware corporation (?the ?Company?) and Jen Hoglin, an individual (the ?Executive?). The Company and the Executive are referred to herein collectively as the ?Parties? and may be |
|
| March 31, 2015 |
EXECUTIVE EMPLOYMENT AGREEMENT EX-10.20 4 perseonexh1020.htm EMPLOYMENT AGREEMENT WITH EFFECTIVE DATE FEBRUARY 17, 2015 BETWEEN THE COMPANY AND JEN HOGLIN. Exhibit 10.20 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into effective as of February 16, 2015 (the “Effective Date”), by and between Perseon Corporation, a Delaware corporation (“the “Company”) and Todd Turnlund |
|
| March 31, 2015 |
SUBSIDIARIES OF THE REGISTRANT EX-21.1 6 perseonexh21.htm SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT None. |
|
| March 31, 2015 |
Exhibit 10.21 PROMISSORY NOTE $750,000.00 Loan No. BSDM01 February 24, 2015 Bellevue, Washington FOR VALUE RECEIVED, PERSEON CORPORATION, a Delaware corporation f/k/a BSD Medical corporation ( "Borrower"), promises to pay, in lawful money of the United States of America, to the order of ACCESS BUSINESS FINANCE, LLC, a Washington limited liability company, ( "Lender") at 14205 S. E. 36th Street, Su |
|
| February 24, 2015 |
EX-99.1 3 ex991.htm EXHIBIT 99.1 PERSEON LAUNCHES AS A NEW LIFE SCIENCES COMPANY IN THE SILICON SLOPES OF UTAH Perseon to Showcase its Leading Microwave Ablation Technology at 40th Annual Scientific Meeting of Society of Interventional Radiology (SIR) Salt Lake City – February 24, 2015 – BSD Medical Corporation (NASDAQ:BSDM) (the Company), a leading provider of medical systems that utilize heat th |
|
| February 24, 2015 |
EXHIBIT 3.1 SECOND CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BSD MEDICAL CORPORATION BSD Medical Corporation, a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: 1. This Second Certificate of Amendment (the “Certificate of Amendment”) amends the provisions of the Corporation |
|
| February 24, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2015 (February 20, 2015) Perseon Corporation (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorpor |
|
| February 11, 2015 |
Other Events, Submission of Matters to a Vote of Security Holders 8-K 1 bsd8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2015 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of |
|
| February 9, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2015 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commissio |
|
| February 3, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2015 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commissio |
|
| January 15, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 bsd.htm BSD MEDICAL CORPORATION 8K 2015-01-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2015 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (Stat |
|
| January 15, 2015 |
BSD Medical Corporation Reports First Quarter 2015 Financial Results Exhibit 99.1 BSD Medical Corporation Reports First Quarter 2015 Financial Results Investor & Analyst Conference Call Today at 2:00 p.m. Eastern Time/12:00 p.m. Mountain Time Salt Lake City – January 15, 2015 – BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD), a leading provider of medical systems that utilize heat therapy to treat cancer, today reported financial results for the fiscal first |
|
| January 14, 2015 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS AGREEMENT is made and shall be effective as of November 10, 2014 (the ?Effective Date?), by and between BSD Medical Corporation, a Delaware corporation (?BSD? or the ?Company?), and Clinton E Carnell Jr., an individual and resident of the state of Utah (the ?Executive?). The Company and the Executive are referred to herein collectively as the ?Parties? and ma |
|
| January 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended November 30, 2014 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-32526 BSD Medical C |
|
| January 12, 2015 |
SC 13G/A 1 p15-0017sc13ga.htm P15-0017 BSD MEDICAL CORPORATION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* BSD Medical Corporation (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 055662100 (CUSIP Number) December 31, 2014 (Date of event which requires filing of this statement) C |
|
| January 12, 2015 |
EX-99.1 2 bsdexh991.htm PRESS RELEASE DATED JANUARY 12, 2015 REGARDING THE COMPANY'S STRATEGY, GROWTH TARGETS AND A CONFERENCE CALL SCHEDULED FOR THURSDAY, JANUARY 15, 2015 Exhibit 99.1 BSD Medical Corporation Outlines Strategy and Revenue Targets for Microwave Ablation Solutions Investor & Analyst Conference Call Scheduled for Thursday, January 15 at 2:00 p.m. Eastern Time/12:00 p.m. Mountain Tim |
|
| January 12, 2015 |
8-K 1 bsd.htm BSD MEDICAL CORPORATION 8K 2015/01-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2015 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State |
|
| December 29, 2014 |
PRSN / Perseon Corporation DEF 14A - - BSD MEDICAL CORPORATION DEF 14A 2014-12-24 DEF 14A 1 bsd.htm BSD MEDICAL CORPORATION DEF 14A 2014-12-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of theSecurities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only |
|
| November 14, 2014 |
EX-99.1 2 bsdexh991.htm PRESS RELEASE DATED NOVEMBER 13, 2014 REGARDING FINANCIAL RESULTS FOR THE FISCAL YEAR ENDED AUGUST 31, 2014 Exhibit 99.1 Contact: Tricia Ross BSD MEDICAL CORPORATION Telephone : 310-622-8226 2188 West 2200 South Email: [email protected] Salt Lake City, Utah 84119-1326 NASDAQ:BSDM For Immediate Release BSD Medical Announces Fiscal Year 2014 Financial Results SALT LAKE CITY, |
|
| November 14, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commissi |
|
| November 13, 2014 |
STOCK OPTION GRANT BSD Medical Corporation Notice of Grant of Stock Option Exhibit 10.8 STOCK OPTION GRANT BSD Medical Corporation Notice of Grant of Stock Option Clinton E. Carnell Jr. 2891 West View Trail Park City, UT 84098 Dear Clint, 1. Grant of Option. BSD Medical Corporation (the "Company"), hereby grants to you an option (the "Option") to purchase common shares of the Company (the "Shares") in connection with your acceptance of an offer to become the President an |
|
| November 13, 2014 |
SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT None. |
|
| November 13, 2014 |
Exhibit 10.7 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (“Agreement”) is made and shall be effective as of the 10th day of November, 2014 (the “Effective Date”), by and between BSD Medical Corporation, a Delaware Corporation (“BSD” or the “Company”) and Harold R. Wolcott, an individual and resident of the State of Utah (“Wolcott” or the “Consultant”). BSD and Wolcott are referred to herein col |
|
| November 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended August 31, 2014 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number: 001-32526 BSD MEDICAL COR |
|
| November 12, 2014 |
8-K 1 bsd8k11102014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of i |
|
| September 19, 2014 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS AGREEMENT is made and shall be effective as of September 16, 2014 (the “Effective Date”), by and between BSD Medical Corporation, a Delaware corporation (“BSD” or the “Company”) and William S. Barth, an individual and resident of the state of Utah (the “Executive”). The Company and the Executive are referred to herein collectively as the “Parties” and may be |
|
| September 19, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commiss |
|
| August 25, 2014 |
SC 13G 1 p14-1831sc13g.htm BSD MEDICAL CORPORATION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BSD Medical Corporation (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 055662100 (CUSIP Number) July 1, 2014 (Date of event which requires filing of this statement) Check the appropriate |
|
| August 13, 2014 |
Exhibit 99.1 BSD MEDICAL CORPORATION Contact: Tricia Ross 2188 West 2200 South Telephone: (310) 622-8226 Salt Lake City, Utah 84119-1326 [email protected] NASDAQ:BSDM For Immediate Release BSD Medical Announces Receipt of Nasdaq Notice of Bid Price Deficiency SALT LAKE CITY, August 13, 2014—BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) announced today that on August 8, 2014, i |
|
| August 13, 2014 |
8-K 1 bsdmedical8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdictio |
|
| August 5, 2014 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commission F |
|
| July 11, 2014 |
EX-99.1 2 exhibit99-1.htm PRESS RELEASE DATED JULY 10, 2014 Exhibit 99.1 Investor Contact: BSD MEDICAL CORPORATION Tricia Ross 2188 West 2200 South Financial Profiles Salt Lake City, Utah 84119-1326 310-622-8226 NASDAQ:BSDM [email protected] For Immediate Release BSD Medical Announces Third Quarter Fiscal 2014 Financial Results Total Revenues Increased 53% with 50% Increase in Disposable Anten |
|
| July 11, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commission F |
|
| July 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 bsd.htm BSD MEDICAL CORPORATION 10Q 2014-05-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended May 31, 2014 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period fr |
|
| July 1, 2014 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorpor |
|
| June 30, 2014 |
Financial Statements and Exhibits 8-K/A 1 bsd.htm BSD MEDICAL CORPORATION 8KA 2014-06-20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32 |
|
| June 27, 2014 |
8-K 1 bsdmed.htm BSD MEDICAL CORPORATION 8K 2014-06-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (Stat |
|
| June 26, 2014 |
FORM OF COMMON STOCK PURCHASE WARRANT BSD MEDICAL CORPORATION EX-4.1 3 bsdexh41.htm FORM OF COMMON STOCK PURCHASE WARRANT Exhibit 4.1 FORM OF COMMON STOCK PURCHASE WARRANT BSD MEDICAL CORPORATION Warrant Shares: Initial Exercise Date: December , 2014 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions here |
|
| June 26, 2014 |
EX-10.1 4 bsdexh101.htm SECURITIES PURCHASE AGREEMENT, DATED AS OF JUNE 25, 2014, BY AND BETWEEN THE COMPANY AND EACH OF THE PURCHASERS IDENTIFIED ON THE SIGNATURE PAGES THERETO Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 25, 2014, between BSD Medical Corporation, a Delaware corporation (the “Company”), and each purchaser ide |
|
| June 26, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 bsd.htm BSD MEDICAL CORPORATION 8K 2014-06-20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State o |
|
| June 26, 2014 |
424B5 1 bsd.htm BSD MEDICAL CORPORATION 424B5 2014-06-25 Filed Pursuant to Rule 424(b)(5) Registration No. 333-184164 Prospectus Supplement (To Prospectus Dated October 11, 2012) BSD MEDICAL CORPORATION 5,500,000 SHARES OF COMMON STOCK WARRANTS TO PURCHASE 4,400,000 SHARES OF COMMON STOCK 4,400,000 SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THE WARRANTS This is an offering on a reasonable be |
|
| June 26, 2014 |
ADDENDUM A INDEMNIFICATION PROVISIONS EX-1.1 2 bsdexh11.htm ENGAGEMENT AGREEMENT, DATED AS OF JUNE 20, 2014, BY AND AMONG THE COMPANY AND MAXIM GROUP LLC Exhibit 1.1 CONFIDENTIAL June 20, 2014 Mr. Harold R. Wolcott, Chief Executive Officer & Director Mr. William S. Barth, Chief Financial Officer BSD Medical Corporation 2188 West 2200 South Salt Lake City, UT 84119-1326 Gentlemen: This letter (the “Agreement”) constitutes the agreement |
|
| June 26, 2014 |
BSD Medical Corporation to Raise $5,225,000 in Registered Direct Offering Exhibit 99.1 BSD Medical Corporation to Raise $5,225,000 in Registered Direct Offering SALT LAKE CITY, UTAH, June 26, 2014 – BSD Medical Corporation (NASDAQCM: BSDM) (BSD), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that it has entered into definitive agreements with institutional investors to raise approximately $5,225,000 in a registered dire |
|
| June 23, 2014 |
Financial Statements and Exhibits, Other Events - BSD MEDICAL CORPORATION 8K 2014-06-20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commission F |
|
| June 23, 2014 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 bsd.htm BSD MEDICAL CORPORATION 8K 2014-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State o |
|
| June 23, 2014 |
Exhibit 10.1 BSD MEDICAL CORPORATION Common Stock (par value $0.001 per share) Termination of At-the-Market Issuance Sales Agreement MLV & Co. LLC 1251 Avenue of the Americas 41st Floor New York, New York 10020 Ladies and Gentlemen: BSD Medical Corporation, a Delaware corporation (the “Company”), and MLV & Co. LLC (“MLV”) are parties to that certain At-the-Market Issuance Sales Agreement (the “Agr |
|
| June 23, 2014 |
Exhibit 10.1 SETTLEMENT AGREEMENT This SETTLEMENT AGREEMENT (the “Agreement”), dated as of June 20, 2014, is by and between BSD Medical Corporation, a Delaware corporation (the “Company”), and Cranshire Capital Master Fund, Ltd. (“Cranshire”). RECITALS A. The Company, Cranshire and other investors are parties to those certain Securities Purchase Agreements dated February 11, 2010, May 3, 2010, Aug |
|
| June 2, 2014 |
- BSD MEDICAL CORPORATION SD 12-31-2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT BSD Medical Corporation (Exact Name of Registrant as Specified in Charter) Delaware 001-32526 75-1590407 (State or Other Jurisdiction of Incorporation) (Commission File No.) (I.R.S. Employer Identification Number) 2188 West 2200 South, Salt Lake City, Utah 84119 (Address of Principal Execu |
|
| June 2, 2014 |
EX-1.02 2 ex102.htm EXHIBIT 1.02 Exhibit 1.02 Conflict Minerals Report of BSD Medical Corporation in Accordance with Rule 13p-1 under the Securities Exchange Act of 1934 This report has been prepared by management of BSD Medical Corporation (herein referred to as “BSD,” the “Company,” “we,” “us,” or “our”). The Company does not have any subsidiaries or variable interest entities that are required |
|
| May 9, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 9, 2014 |
BSD MEDICAL CORPORATION COMMON STOCK 424B5 1 bsd.htm BSD MEDICAL CORPORATION 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-184164 Prospectus Supplement (To Prospectus Dated October 11, 2012) BSD MEDICAL CORPORATION $8,000,000 COMMON STOCK We are offering up to $8,000,000 of our common stock from time to time through our sales agent, MLV & Co. LLC (“MLV”). We have entered into an At-the-Market Issuance Sales Agreement (t |
|
| May 9, 2014 |
Exhibit 10.1 BSD MEDICAL CORPORATION Common Stock (par value $0.001 per share) At-the-Market Issuance Sales Agreement May 9, 2014 MLV & Co. LLC 1251 Avenue of the Americas 41st Floor New York, New York 10020 Ladies and Gentlemen: BSD Medical Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV”), as follows: 1. Issuance and Sale o |
|
| April 29, 2014 |
8-K 1 bsdmedical8k.htm BSD MEDICAL CORPORATION FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (St |
|
| April 29, 2014 |
EX-10.2 3 exhibit10-2.htm PRESS RELEASE DATED APRIL 29, 2014 ANNOUNCING A CHIEF EXECUTIVE OFFICER SUCCESSION PLAN Exhibit 10.2 Contact: William Barth BSD MEDICAL CORPORATION Telephone: (801) 972-5555 2188 West 2200 South Facsimile: (801) 972-5930 Salt Lake City, Utah 84119-1326 Email: [email protected] NASDAQ:BSDM For Immediate Release BSD Medical Board of Directors Announces CEO Succession Plan |
|
| April 29, 2014 |
EX-10.1 2 exhibit10-1.htm LETTER AGREEMENT, DATED APRIL 28, 2014, BETWEEN THE COMPANY AND HAROLD R. WOLCOTT Exhibit 10.1 April 28, 2014 Mr. Harold R. Wolcott, President and CEO BSD Medical Corporation 2188 West 2200 South Salt Lake City, Utah 84119 Dear Mr. Wolcott: This Letter Agreement will set forth and confirm the agreement which has been reached between you and BSD Medical Corporation (the “C |
|
| April 23, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction of incorporation) (Commission |
|
| April 23, 2014 |
Exhibit 99.1 Contact: William Barth BSD MEDICAL CORPORATION Telephone: (801) 972-5555 2188 West 2200 South Facsimile: (801) 972-5930 Salt Lake City, Utah 84119-1326 Email: [email protected] NASDAQ:BSDM For Immediate Release BSD Medical Corporation (BSDM) Receives Approval to Transfer Listing to NASDAQ Capital Market SALT LAKE CITY—April 23, 2014 — BSD Medical Corporation (NASDAQ:BSDM) (Company or |
|
| April 18, 2014 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K 1 bsdmedical8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdictio |
|
| April 10, 2014 |
EX-99.1 2 bsdhtm.htm PRESS RELEASE DATED APRIL 9, 2014 REGARDING FINANCIAL RESULTS FOR THE FISCAL QUARTER ENDED FEBRUARY 28, 2014 Exhibit 99.1 BSD MEDICAL CORPORATION Contact: William Barth 2188 West 2200 South Telephone: (801) 972-5555 Salt Lake City, Utah 84119-1326 Facsimile: (801) 972-5930 NASDAQ:BSDM Email: [email protected] For Immediate Release BSD Medical Announces Second Quarter Fiscal 2 |
|
| April 10, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 bsd.htm BSD MEDICAL CORPORATION 8K 2014-04-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-10783 75-1590407 (State or |
|
| April 9, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended February 28, 2014 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-32526 BSD Medical C |
|
| March 7, 2014 |
Exhibit 99.1 Contact: William Barth BSD MEDICAL CORPORATION Telephone: (801) 972-5555 2188 West 2200 South Facsimile: (801) 972-5930 Salt Lake City, Utah 84119-1326 Email: [email protected] NASDAQ:BSDM For Immediate Release BSD Medical’s Fiscal Second Quarter Revenues Increase 106% to $1.7 Million Revenues for the First Half of Fiscal 2014 Increase 104% to $3.0 million Company to Report Full Seco |
|
| March 7, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 bsdmedical8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-32526 75-1590407 (State or other jurisdiction |
|
| March 5, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 10-K/A 1 bsd.htm BSD MEDICAL CORPORATION 10K 2013-08-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended August 31, 2013 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the T |
|
| March 5, 2014 |
2188 West 2200 South, Salt Lake City, UT 84119 – Ph 801.972.5555 – Fx 801.972.5930 – www.bsdmedical.com March 5, 2014 VIA EDGAR Martin F. James United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: BSD Medical Corporation Form 10-K for the fiscal year ended August 31, 2013 Filed November 14, 2013 File No. 001-32526 Dear Mr. |
|
| February 18, 2014 |
PRSN / Perseon Corporation / Sennewald Gerhard W - SCHEDULE 13G AMENDMENT NO. 1 Passive Investment SC 13G/A 1 sch13ga.htm SCHEDULE 13G AMENDMENT NO. 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) BSD Medical Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 055662100 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 18, 2014 |
PRSN / Perseon Corporation / Turner Paul F - SCHEDULE 13G AMENDMENT NO. 3 Passive Investment SC 13G/A 1 sch13ga.htm SCHEDULE 13G AMENDMENT NO. 3 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) BSD Medical Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 055662100 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 7, 2014 |
Submission of Matters to a Vote of Security Holders 8-K 1 bsdmedical8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-10783 75-1590407 (State or other jurisdictio |
|
| February 6, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-10783 75-1590407 (State or other jurisdiction of incorporation) (Commission |
|
| February 6, 2014 |
Exhibit 99.1 Contact: William Barth BSD MEDICAL CORPORATION Telephone: (801) 972-5555 2188 West 2200 South Facsimile: (801) 972-5930 Salt Lake City, Utah 84119-1326 Email: [email protected] NASDAQ:BSDM For Immediate Release BSD Medical Announces Taiwan Food and Drug Administration Marketing and Import License Approval for the BSD-2000 is in Process SALT LAKE CITY—February 6, 2014 — BSD Medical Co |
|
| January 9, 2014 |
10-Q 1 bsdmedical10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 [Missing Graphic Reference] FORM 10-Q (Mark One) ý Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended November 30, 2013 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transi |
|
| January 9, 2014 |
Exhibit 99.1 Contact: William Barth BSD MEDICAL CORPORATION Telephone: (801) 972-5555 2188 West 2200 South Facsimile: (801) 972-5930 Salt Lake City, Utah 84119-1326 Email: [email protected] NASDAQ:BSDM For Immediate Release BSD Medical Announces First Quarter Fiscal 2014 Financial Results SALT LAKE CITY,January 9, 2014—BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a |
|
| January 9, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2014 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-10783 75-1590407 (State or other jurisdiction of incorporation) (Commission F |
|
| December 30, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| November 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended August 31, 2013 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number: 001-32526 BSD MEDICAL COR |
|
| November 7, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 bsd.htm BSD MEDICAL CORPORATION 8K 2013-11-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2013 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-10783 75-1590407 (State |
|
| November 7, 2013 |
EX-99 2 bsdexh991.htm PRESS RELEASE DATED NOVEMBER 7, 2013 REGARDING FINANCIAL RESULTS FOR THE FISCAL YEAR ENDED AUGUST 31, 2013 Exhibit 99.1 Contact: William Barth BSD MEDICAL CORPORATION Telephone: (801) 972-5555 2188 West 2200 South Facsimile: (801) 972-5930 Salt Lake City, Utah 84119-1326 Email: [email protected] NASDAQ:BSDM For Immediate Release BSD Medical Announces Fiscal Year 2013 Financi |
|
| July 10, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended May 31, 2013 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-32526 BSD Medical Corpor |
|
| May 29, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2013 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-10783 75-1590407 (State or other jurisdiction of incorporation) (Commission File |
|
| May 29, 2013 |
EX-10.1 2 bsdmedicalexh101.htm EMPLOYMENT AGREEMENT DATED MAY 22, 2013 BETWEEN THE COMPANY AND HAROLD R. WOLCOTT Exhibit 10.1 EMPLOYMENT AGREEMENT THIS AGREEMENT is made and shall be effective as of May 22, 2013 (the “Effective Date”), by and between BSD Medical Corporation, a Delaware corporation (“BSD” or the “Company”) and Harold R. Wolcott, an individual and resident of the state of Utah (the |
|
| April 12, 2013 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2013 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-10783 75-1590407 (State or other jurisdiction of incorporat |
|
| April 9, 2013 |
EX-10.1 4 exhibit10-1.htm EXHIBIT10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 9, 2013, is by and among BSD Medical Corporation, a Delaware corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”). RECITALS A. The Company |
|
| April 9, 2013 |
FORM OF WARRANT BSD MEDICAL CORPORATION WARRANT TO PURCHASE COMMON STOCK Exhibit 4.1 FORM OF WARRANT BSD MEDICAL CORPORATION WARRANT TO PURCHASE COMMON STOCK Warrant No.: Date of Issuance: April , 2013 (“Issuance Date”) BSD Medical Corporation, a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, , the registered holder hereof or its permitted assigns (the “Hold |
|
| April 9, 2013 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-184164 Prospectus Supplement (To Prospectus Dated October 11, 2012) BSD MEDICAL CORPORATION 4,065,042 SHARES OF COMMON STOCK WARRANTS TO PURCHASE 3,048,782 SHARES OF COMMON STOCK 3,048,782 SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THE WARRANTS We are offering directly to selected investors up to 4,065,042 shares of our common stock and w |
|
| April 9, 2013 |
PLACEMENT AGENCY AGREEMENT April 9, 2013 Exhibit 1.1 PLACEMENT AGENCY AGREEMENT April 9, 2013 Roth Capital Partners, LLC 24 Corporate Plaza Newport Beach, CA 92660 Ladies and Gentlemen: BSD Medical Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions herein, to issue and sell an aggregate of up to (i) 4,065,042 shares (the “Shares”) of its common stock, $0.001 par value per share (the “Common |
|
| April 9, 2013 |
Exhibit 99.1 BSD MEDICAL CORPORATION Contact: William Barth 2188 West 2200 South Telephone: (801) 972-5555 Salt Lake City, Utah 84119-1326 Facsimile: (801) 972-5930 Email: [email protected] NASDAQ:BSDM For Immediate Release BSD Medical Announces Registered Direct Offering of Common Stock and Warrants in Aggregate Amount of $5 Million SALT LAKE CITY, Utah –– April 9, 2013 ––BSD Medical Corporation |
|
| April 9, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2013 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-10783 75-1590407 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 8, 2013 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Contact: William (Bill) S. Barth BSD MEDICAL CORPORATION Telephone: (801) 972-5555 2188 West 2200 South Facsimile: (801) 972-5930 Salt Lake City, Utah 84119-1326 Email: [email protected] NASDAQ:BSDM For Immediate Release BSD Medical Announces Exclusive Multi-Million Dollar Distribution Agreement with Terumo Europe NV for MicroThermX® Microwave C |
|
| April 8, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2013 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-10783 75-1590407 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 5, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended February 28, 2013 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-32526 BSD Medical C |
|
| March 29, 2013 |
Exhibit 99.1 Contact: William Barth BSD MEDICAL CORPORATION Telephone: (801) 972-5555 2188 West 2200 South Facsimile: (801) 972-5930 Salt Lake City, Utah 84119-1326 Email: [email protected] NASDAQ:BSDM BSD Medical Announces Financial Results for Second Quarter and First Six Months of Fiscal 2013 SALT LAKE CITY, March 28, 2013—BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical. |
|
| March 29, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 bdsmedical8k20130329.htm BSD MEDICAL CORPORATION FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2013 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-10783 75-15904 |
|
| February 13, 2013 |
PRSN / Perseon Corporation / Turner Paul F - SCHEDULE 13G AMENDMENT NO. 2 Passive Investment SC 13G/A 1 sch13ga.htm SCHEDULE 13G AMENDMENT NO. 2 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) BSD Medical Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 055662100 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 8, 2013 |
Submission of Matters to a Vote of Security Holders - BSD MEDICAL CORPORATION 8K 2103-02-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2013 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-10783 75-1590407 (State or other jurisdiction of incorporation) (Commission |
|
| January 14, 2013 |
EX-99.1 2 exhibit99-1.htm PRESS RELEASE DATED JANUARY 10, 2013 Exhibit 99.1 Contact: Bill Barth BSD MEDICAL CORPORATION Telephone: (801) 972-5555 2188 West 2200 South Facsimile: (801) 972-5930 Salt Lake City, Utah 84119-1326 Email: [email protected] NASDAQ:BSDM For Immediate Release BSD Medical Announces First Quarter Fiscal 2013 Financial Results SALT LAKE CITY, January 10, 2013—BSD Medical Corp |
|
| January 14, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2013 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-10783 75-1590407 (State or other jurisdiction of incorporation) (Commission |
|
| January 9, 2013 |
EX-10.1 2 bsdmedical10qexh101.htm SEPARATION AGREEMENT AND RELEASE OF ALL CLAIMS BETWEEN THE COMPANY AND DENNIS GAUGER EXHIBIT 10.1 This document affects your legal rights. You are advised to consult with an attorney or other counsel of your choice prior to signing this Agreement. SEPARATION AGREEMENT AND RELEASE OF ALL CLAIMS THIS SEPARATION AGREEMENT AND RELEASE OF ALL CLAIMS (“Agreement”) is ma |
|
| January 9, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended November 30, 2012 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-32526 BSD Medical C |
|
| December 28, 2012 |
BSD MEDICAL CORPORATION 2188 West 2200 South, Salt Lake City, Utah 84119 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS OF BSD MEDICAL CORPORATION February 6, 2013 TO THE STOCKHOLDERS OF BSD MEDICAL CORPORATION: The annual meeting of the stockholders (the “Annual Meeting”) of BSD Medical Corporation (the “Company” or “BSD”) will be held on February 6, 2013, at the Little America Hotel located at 500 South Main Street, Salt Lake City, Utah 84101. |
|
| December 11, 2012 |
8-K 1 bsd8k20121210.htm BSD MEDICAL CORPORATION FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2012 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other juri |
|
| December 11, 2012 |
EX-99.1 2 ex99-1.htm PRESS RELEASE DATED DECEMBER 11, 2012 ANNOUNCING APPOINTMENT OF WILLIAM S. BARTH AS CHIEF FINANCIAL OFFICER AND SECRETARY EXHIBIT 99.1 For Immediate Release BSD Medical Appoints William Barth as Chief Financial Officer SALT LAKE CITY—December 11, 2012 — BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utili |
|
| December 3, 2012 |
8-K 1 bsd8k20121130.htm BSD MEDICAL CORPORATION FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2012 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other juri |
|
| November 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended August 31, 2012 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number: 001-32526 BSD MEDICAL COR |
|
| September 28, 2012 |
EX-4.7 3 exhibit4-7.htm FORM OF SUBORDINATED INDENTURE Exhibit 4.7 BSD MEDICAL CORPORATION TO [], as Trustee INDENTURE Dated as of , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE ONE DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 101. Definitions 1 SECTION 102. Compliance Certificates and Opinions 11 SECTION 103. Form of Documents Delivered to Trustee 12 SECTION |
|
| September 28, 2012 |
Exhibit 4.6 BSD MEDICAL CORPORATION TO [], as Trustee INDENTURE Dated as of , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE ONE DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 101. Definitions 1 SECTION 102. Compliance Certificates and Opinions 10 SECTION 103. Form of Documents Delivered to Trustee 10 SECTION 104. Acts of Holders 11 SECTION 105. Notices, etc., to the T |
|
| September 28, 2012 |
- BSD MEDICAL CORPORATION FORM S-3 S-3 1 bsdmedicalcorporationforms3.htm BSD MEDICAL CORPORATION FORM S-3 As filed with the Securities and Exchange Commission on September 28, 2012 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 75-1590 |
|
| July 26, 2012 |
BSD Medical Corporation to Host Investor And Analyst Webinar Update Featuring MicroThermX® on August 7 Live Webinar on the MicroThermX® Microwave Ablation System Scheduled for Tuesday, August 7 at 2:00 p. |
|
| July 26, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2012 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-10783 75-1590407 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 9, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended May 31, 2012 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-32526 BSD Medical Corpor |
|
| July 6, 2012 |
Exhibit 99.1 Contact: Dennis Gauger BSD MEDICAL CORPORATION Telephone: (801) 972-5555 2188 West 2200 South Facsimile: (801) 972-5930 Salt Lake City, Utah 84119-1326 Email: [email protected] NASDAQ:BSDM For Immediate Release BSD Medical Announces Third Quarter Fiscal 2012 Financial Results SALT LAKE CITY, July 6, 2012—BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a l |
|
| July 6, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2012 BSD MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-10783 75-1590407 (State or other jurisdiction of incorporation) (Commission File |
